Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more
Chongqing Zhifei Bio Products (300122) - Total Liabilities
Latest total liabilities as of September 2025: CN¥16.79 Billion CNY
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has total liabilities worth CN¥16.79 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chongqing Zhifei Bio Products - Total Liabilities Trend (2007–2024)
This chart illustrates how Chongqing Zhifei Bio Products's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chongqing Zhifei Bio Products Competitors by Total Liabilities
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Codan Ltd
AU:CDA
|
Australia | AU$380.98 Million |
|
Beijing GeoEnviron Engineering
SHG:603588
|
China | CN¥16.72 Billion |
|
Retail Opportunity Investments
NASDAQ:ROIC
|
USA | $1.66 Billion |
|
CSI Solar Co. Ltd. A
SHG:688472
|
China | CN¥45.64 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$4.90 Billion |
|
Sh Belling
SHG:600171
|
China | CN¥648.87 Million |
|
Shanghai Jin Jiang International Hotels Development Co Ltd A
SHG:600754
|
China | CN¥29.58 Billion |
|
Par Pacific Holdings Inc
NYSE:PARR
|
USA | $2.68 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Chongqing Zhifei Bio Products's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Zhifei Bio Products's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Zhifei Bio Products (2007–2024)
The table below shows the annual total liabilities of Chongqing Zhifei Bio Products from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥19.08 Billion | +1.88% |
| 2023-12-31 | CN¥18.73 Billion | +36.02% |
| 2022-12-31 | CN¥13.77 Billion | +11.12% |
| 2021-12-31 | CN¥12.39 Billion | +77.85% |
| 2020-12-31 | CN¥6.97 Billion | +34.10% |
| 2019-12-31 | CN¥5.20 Billion | +97.59% |
| 2018-12-31 | CN¥2.63 Billion | +125.04% |
| 2017-12-31 | CN¥1.17 Billion | +520.77% |
| 2016-12-31 | CN¥188.21 Million | -11.39% |
| 2015-12-31 | CN¥212.40 Million | -17.26% |
| 2014-12-31 | CN¥256.72 Million | +29.26% |
| 2013-12-31 | CN¥198.61 Million | +41.62% |
| 2012-12-31 | CN¥140.24 Million | -4.10% |
| 2011-12-31 | CN¥146.22 Million | +116.35% |
| 2010-12-31 | CN¥67.59 Million | +1.89% |
| 2009-12-31 | CN¥66.33 Million | -46.09% |
| 2008-12-31 | CN¥123.05 Million | -14.71% |
| 2007-12-31 | CN¥144.27 Million | -- |